Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes

Mayfield, Karla, Siskind, Dan, Winckel, Karl, Russell, Anthony W., Kisely, Steve, Smith, Greg and Hollingworth, Samantha (2016) Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. Journal of Psychopharmacology, 30 3: 227-236. doi:10.1177/0269881115625496


Author Mayfield, Karla
Siskind, Dan
Winckel, Karl
Russell, Anthony W.
Kisely, Steve
Smith, Greg
Hollingworth, Samantha
Title Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Journal name Journal of Psychopharmacology   Check publisher's open access policy
ISSN 0269-8811
1461-7285
Publication date 2016-01-22
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1177/0269881115625496
Open Access Status Not Open Access
Volume 30
Issue 3
Start page 227
End page 236
Total pages 10
Place of publication London, United Kingdom
Publisher Sage Publications
Collection year 2017
Language eng
Formatted abstract
Clozapine is the most effective antipsychotic, but its use is tempered by adverse metabolic effects such as weight gain, glucose intolerance and type II diabetes. Current interventions do not facilitate compelling or sustained improvement in metabolic status. Recent studies suggest that glucagon-like peptide-1 (GLP-1) may play a key role in clozapine’s metabolic effects, possibly suggesting that clozapine-associated obesity and diabetes are mediated independently through reduced GLP-1. As a result, GLP-1 agonists could show promise in reversing antipsychotic-induced metabolic derangements, providing mechanistic justification that they may represent a novel approach to treat, and ultimately prevent, both diabetes and obesity in patients on clozapine. GLP-1 agonists are already used for diabetes, and they provide a unique combination of glycaemic improvement and metabolically relevant weight loss in diabetic and non-diabetic patients, in the context of a currently favourable safety proļ¬le. Using GLP-1 agonists for clozapine-associated obesity and diabetes could be a potentially effective intervention that may reduce cardiometabolic morbidity and mortality in this vulnerable patient population.
Keyword Clozapine
Antipsychotic
GLP-1
Metabolic
Schizophrenia
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: HERDC Pre-Audit
Admin Only - School of Medicine
School of Medicine Publications
School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 25 Jan 2016, 17:36:13 EST by Mr Karl Winckel on behalf of School of Pharmacy